The production of vaccines against him covid-19 could reach 10 billion dose in 2021, said this February 23, 2021, the general director of the International Federation of Pharmaceutical Producers (IFPMA), Thomas Cueni.
“We are seeing a increase of production because they are working 24 hours a day, seven days a week, “said the head of the entity representing the interests of the pharmaceutical industry.
Cueni rejected the critics that your sector is receiving for privileging the supply from vaccines to rich countries with which the different companies that they have managed to develop effective vaccines have signed contracts.
The United States alone has received 25% of all vaccines available globally and the European Union as a whole 12.6%.
Cueni recalled that the US was the first country to invest a amount important of money public to accelerate the development of one or more vaccines against covid, which has already caused more than half a million deaths in this country.
He also indicated that the countries that are now receiving more vaccines signed advance purchase contracts several months ago and that “these cannot be ignored”.
At a press conference, Cueni showed statistics Recent shows that also developing countries, such as China (14.7%), Indonesia (9.8%) or Brazil (4.5%), have received a proportion considerable number of vaccines.
These countries, like Turkey, Morocco or Chile, have managed to advance in their vaccination programs against covid by sourcing the two main vaccines produced in China by companies Sinopharm y Sinovac.
Instead, the vaccines used in North America and Europe correspond mainly to those developed by Pfizer / BioNTech and Moderna, who were the first to be approved by internationally recognized regulatory bodies.
In addition, both are the ones that effectiveness have shown (greater than 92% after two doses) among all vaccines available Until now.
The IFPMA estimates that the demand is currently at least twice the production capacity, facing multiple obstacles that go beyond the formulation of the serum itself, such as the manufacture of glass vials and the procedure for filling them, which must be carried out in special facilities that are limited.
Cueni considered unfounded critics to pharmaceutical companies and recalled that thanks to efforts and the collaboration that several of them have established has been possible to “double the capacity of manufacture in 2021, something that some time ago was thought to be impossible. “
He argued that projections current indicate that COVAX, the platform created by World Health Organization (WHO) To ensure fair access to vaccines, it will be able to receive the 2 billion dose I was aiming for this year.
His intention is that at least 20% of the population higher risk in low- and middle-income countries is immunized with them.
Regardless of the type of vaccine, the largest production capacity of vaccines are in China, followed by the United States, the European Union and India.
These days, the World Trade Organization (WTO), which like the WHO is based in Geneva, will discuss a proposal jointly between India and South Africa to temporarily and exceptionally revoke patents that protect the intellectual property of vaccines.
The developing countries support this idea, which is flatly rejected by the rich countries that are home to much of the industry that would be affected.
Cueni said that innovation has been the engine of the rapid development of vaccines against covid and to go forward with such initiative it would be “a terrible signal for preparedness for future pandemics” as it would discourage investments from the private sector